15
Views
47
CrossRef citations to date
0
Altmetric
Original Article

Immunocytochemically Detectable TGF-β Associated with Malignancy in Thyroid Epithelial Neoplasia

, , , , &
Pages 149-155 | Received 05 Jun 1989, Accepted 27 Jul 1989, Published online: 11 Jul 2009
 

Abstract

The possible role of changes in TGF-β expression in the multistage development of thyroid cancer was assessed. The presence of TGF-β1 in thyroid epithelial cells was analyzed in sections of normal and tumor tissue using an immunoperoxidase technique employing an antibody directed against the amino-terminal 30 amino acids of mature TGF-β1. Specific immunostaining was clearly detected in epithelial cells in 58% of malignant thyroid tumours (including follicular, papillary, and anaplastic variants). However, no positive cells were seen in any of 7 benign tumors nor in any normal thyroid epithelium. Within the cancer group as a whole, there was no significant correlation with pathological grade or clinical stage of tumor but in one subgroup–follicular carcinomas–a significant association was noted between TGF-β immunostaining and the presence of a specific mutation of the H-ras oncogene (codon 61, glnarg). We conclude that a major alteration in expression of TGF-β occurs specifically in the malignant stage of tumor development in thyroid follicular epithelium and speculate on its possible role in this process.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.